Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Anat Rec (Hoboken) ; 306(1): 124-142, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-35656925

RESUMEN

OBJECTIVE: The development of bipedalism is a very complex activity that contributes to shaping the anatomy of the foot. The talus, which starts ossifying in utero, may account for the developing stages from the late gestational phase onwards. Here, we explore the early development of the talus in both its internal and external morphology to broaden the knowledge of the anatomical changes that occur during early development. MATERIALS AND METHODS: The sample consists of high-resolution microCT scans of 28 modern juvenile tali (from 36 prenatal weeks to 2 years), from a broad chronological range from the Late Roman period to the 20th century. We applied geometric morphometric and whole-bone trabecular analysis to investigate the early talar morphological changes. RESULTS: In the youngest group (<6 postnatal months), the immature external shell is accompanied by an isotropic internal structure, with thin and densely packed trabeculae. After the initial attempts of locomotion, bone volume fraction decreases, while anisotropy and trabecular thickness increase. These internal changes correspond to the maturation of the external shell, which is now more defined and shows the development of the articular surfaces. DISCUSSION: The internal and external morphology of the human talus reflects the diverse load on the foot during the initial phases of the bipedal locomotion, with the youngest group potentially reflecting the lack of readiness of the human talus to bear forces and perform bipedal walking. These results highlight the link between mechanical loading and bone development in the human talus during the acquisition of bipedalism, providing new insight into the early phases of talar development.


Asunto(s)
Caminata , Humanos , Microtomografía por Rayos X
2.
Diagnostics (Basel) ; 13(1)2022 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-36611342

RESUMEN

Metal components of hip prostheses cause severe artifacts in CT images, influencing diagnostic accuracy. Metal artifact reduction (MAR) software and virtual monoenergetic reconstructions on dual-energy CT (DECT) systems are possible solutions that should be considered. In this study, we created a customized adjustable phantom to quantify the severity of artifacts on periprosthetic tissues (cortical and spongious bone, soft tissues) for hip prostheses. The severity of artifacts was classified by different thresholds of deviation from the CT numbers for reference objects not affected by artifacts. The in vitro setup was applied on four unilateral and three bilateral configurations of hip prostheses (made of titanium, cobalt, and stainless steel alloys) with a DECT system, changing the energy of virtual monoenergetic reconstructions, with and without MAR. The impact of these tools on the severity of artifacts was scored, looking for the best scan conditions for the different configurations. For titanium prostheses, the reconstruction at 110 keV, without MAR, always minimized the artifacts. For cobalt and stainless-steel prostheses, MAR should always be applied, while monoenergetic reconstruction alone did not show clear advantages. The available tools for reducing metal artifacts must therefore be applied depending on the examined prosthetic configuration.

3.
Aging Cell ; 20(1): e13285, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33393189

RESUMEN

Hutchinson-Gilford progeria syndrome (HGPS) causes premature aging in children, with adipose tissue, skin and bone deterioration, and cardiovascular impairment. In HGPS cells and mouse models, high levels of interleukin-6, an inflammatory cytokine linked to aging processes, have been detected. Here, we show that inhibition of interleukin-6 activity by tocilizumab, a neutralizing antibody raised against interleukin-6 receptors, counteracts progeroid features in both HGPS fibroblasts and LmnaG609G/G609G progeroid mice. Tocilizumab treatment limits the accumulation of progerin, the toxic protein produced in HGPS cells, rescues nuclear envelope and chromatin abnormalities, and attenuates the hyperactivated DNA damage response. In vivo administration of tocilizumab reduces aortic lesions and adipose tissue dystrophy, delays the onset of lipodystrophy and kyphosis, avoids motor impairment, and preserves a good quality of life in progeroid mice. This work identifies tocilizumab as a valuable tool in HGPS therapy and, speculatively, in the treatment of a variety of aging-related disorders.


Asunto(s)
Interleucina-6/metabolismo , Progeria/genética , Envejecimiento , Animales , Humanos , Ratones , Progeria/patología
4.
Magn Reson Med ; 85(6): 3353-3369, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33349979

RESUMEN

PURPOSE: Single-sided 1 H-NMR is proposed for the estimation of morphological parameters of trabecular bone, and potentially the detection of pathophysiological alterations of bone structure. In this study, a new methodology was used to estimate such parameters without using an external reference signal, and to study intratrabecular and intertrabecular porosities, with a view to eventually scanning patients. METHODS: Animal trabecular bone samples were analyzed by a single-sided device. The Carr-Purcell-Meiboom-Gill sequence of 1 H nuclei of fluids, including marrow, confined inside the bone, was analyzed by quasi-continuous T2 distributions and separated into two 1 H pools: short and long T2 components. The NMR parameters were estimated using models of trabecular bone structure, and compared with the corresponding micro-CT. RESULTS: Without any further assumptions, the internal reference parameter (short T2 signal intensity fraction) enabled prediction of the micro-CT parameters BV/TV (volume of the trabeculae/total sample volume) and BS/TV (external surface of the trabeculae/total sample volume) with linear correlation coefficient >0.80. The assignment of the two pools to intratrabecular and intertrabecular components yielded an estimate of average intratrabecular porosity (33 ± 5)%. Using the proposed models, the NMR-estimated BV/TV and BS/TV were found to be linearly related to the corresponding micro-CT values with high correlation (>0.90 for BV/TV; >0.80 for BS/TV) and agreement coefficients. CONCLUSION: Low-field, low-cost portable devices that rely on intrinsic magnetic field gradients and do not use ionizing radiation are viable tools for in vitro preclinical studies of pathophysiological structural alterations of trabecular bone.


Asunto(s)
Huesos , Hueso Esponjoso , Animales , Huesos/diagnóstico por imagen , Hueso Esponjoso/diagnóstico por imagen , Humanos , Imagen por Resonancia Magnética , Porosidad , Microtomografía por Rayos X
5.
Exp Gerontol ; 130: 110784, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31794853

RESUMEN

The transgenic LmnaG609G progeric mouse represents an outstanding animal model for studying the human Hutchinson-Gilford Progeria Syndrome (HGPS) caused by a mutation in the LMNA gene, coding for the nuclear envelope protein Lamin A/C, and, as an important, more general scope, for studying the complex process governing physiological aging in humans. Here we give a comprehensive description of the peculiarities related to the breeding of LmnaG609G mice over a prolonged period of time, and of many features observed in a large colony for a 2-years period. We describe the breeding and housing conditions underlining the possible interference of the genetic background on the phenotype expression. This information represents a useful tool when planning and interpreting studies on the LmnaG609G mouse model, complementing any specific data already reported in the literature about this model since its production. It is also particularly relevant for the heterozygous mouse, which mirrors the genotype of the human pathology however requires an extended time to manifest symptoms and to be carefully studied.


Asunto(s)
Cruzamiento , Heterocigoto , Homocigoto , Lamina Tipo A/genética , Progeria/genética , Animales , Modelos Animales de Enfermedad , Proteínas de la Membrana/genética , Ratones , Mutación , Fenotipo
6.
Neurol Res ; 31(7): 687-91, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19061540

RESUMEN

OBJECTIVE: Previous reports showed the reduction of dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. In this work, we sought to investigate the possible correlation between central and peripheral dopamine transporter immunoreactivity values in a group of 11 drug-naive patients with Parkinson's disease. METHODS: Densitometric measurements of dopamine transporter immunoreactivity in peripheral blood lymphocytes was accomplished as described recently, using a monoclonal antidopamine transporter antibody. Dopamine transporter binding in the caudate and putamen nuclei was measured by means of (123)I-fluopane single-photon emission computed tomography in the same patients. RESULTS: The results failed to show any significant correlation between dopamine transporter immunoreactivity in peripheral blood lymphocytes and the caudate or putamen dopamine transporter binding. Moreover, dopamine transporter immunoreactivity in peripheral blood lymphocytes was reduced also in the single patient with normal striatal dopamine transporter binding. DISCUSSION: These results indicate the lack of correlation between central and peripheral dopamine transporter reduction in Parkinson's disease, using the methodologies applied herein. They therefore suggest that the two phenomena are unlikely to share a common pathogenetic mechanism.


Asunto(s)
Núcleo Caudado/metabolismo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Linfocitos/metabolismo , Enfermedad de Parkinson/metabolismo , Putamen/metabolismo , Adulto , Anciano , Núcleo Caudado/diagnóstico por imagen , Femenino , Humanos , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/sangre , Enfermedad de Parkinson/patología , Putamen/diagnóstico por imagen , Tomografía Computarizada de Emisión de Fotón Único/métodos , Tropanos
7.
Respiration ; 75(4): 461-5, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-16825752

RESUMEN

Nocardiosis is a rare and potentially life-threatening infection caused by several species of the Nocardia genus. Most cases occur in immunocompromised patients, and a delay in establishing the diagnosis is common due to the non-specific clinical presentations and the difficulty in cultivating Nocardia. Although the majority of pulmonary nocardiosis cases are caused by Nocardia asteroides, cases of human infection due to N. farcinica are increasingly diagnosed due to recent developments in taxonomy and diagnostic methods. N. farcinica is a separate species from N. asteroides and appears to be more virulent and resistant to antibiotics. Herein, we describe the case of a 65-year-old HIV-negative immunocompromised patient with a fulminant bilateral pulmonary nocardiosis while on empirical treatment with trimethoprim/sulfamethoxazole and imipenem. Post-mortem diagnosis of N. farcinica infection was performed by means of DNA amplification and sequencing of the 65-kDa bacterial heat shock protein.


Asunto(s)
Seronegatividad para VIH , Proteínas de Choque Térmico/genética , Huésped Inmunocomprometido , Nocardiosis/diagnóstico , Nocardia/aislamiento & purificación , Neumonía Bacteriana/diagnóstico , Anciano , Resultado Fatal , Femenino , Humanos , Nocardia/genética , Nocardiosis/inmunología , Nocardiosis/microbiología , Neumonía Bacteriana/inmunología , Neumonía Bacteriana/microbiología , Reacción en Cadena de la Polimerasa , Análisis de Secuencia de ADN
8.
BMC Infect Dis ; 7: 36, 2007 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-17470274

RESUMEN

BACKGROUND: HIV-infected subjects have high incidence rates of Staphylococcus aureus infections, with both methicillin-susceptible and methicillin-resistant (MRSA) strains. Possible explanations could include the high burden of colonization, the behavioral risk factors, and the frequent exposures to health care facilities of HIV-infected patients. The purpose of the study was to assess the risk factors for clinically- significant methicillin-resistant Staphylococcus aureus (CS-MRSA) infections in HIV-infected patients admitted to Infectious Diseases Units. METHODS: From January 1, 2002 to December 31, 2005, we conducted a retrospective case-control (1:2) study. We identified all the cases of CS-MRSA infections in HIV-infected patients admitted to the National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani" in the 4-year study period. A conditional logistic regression model was used to identify risk factors for CS-MRSA infection. RESULTS: We found 27 CS-MRSA infections, i.e. 0.9 CS-MRSA infections per 100 HIV-infected individuals cared for in our Institute. At multivariate analysis, independent predictors of CS-MRSA infection were cumulative hospital stay, invasive procedures in the previous year, and low CD4 cell count. Particularly, the risk for CS-MRSA increased by 14% per an increase of 5 days hospitalization in the previous year. Finally, we identified a low frequency of community-acquired MRSA infections (only 1 of 27; 3.7%) among HIV-infected patients. CONCLUSION: Clinicians should be aware of the risk for CS-MRSA infection in the clinical management of HIV-infected patients, especially in those patients with a low CD4 cell count, longer previous hospital stay, and previous invasive procedures.


Asunto(s)
Infección Hospitalaria/microbiología , Infecciones por VIH/complicaciones , Hospitalización , Resistencia a la Meticilina , Infecciones Estafilocócicas/complicaciones , Adulto , Recuento de Linfocito CD4 , Estudios de Casos y Controles , Femenino , Humanos , Tiempo de Internación , Masculino , Análisis Multivariante , Oportunidad Relativa , Estudios Retrospectivos , Factores de Riesgo , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/patogenicidad
10.
Emerg Infect Dis ; 11(7): 1128-30, 2005 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16022797

RESUMEN

Two cases of community-acquired septicemia caused by serotype-O1 Yersinia pseudotuberculosis were diagnosed in middle-aged, HIV-positive, immunodeficient patients during an 8-month period. Bacterial isolates were genetically indistinguishable, but no epidemiologic link between the 2 patients was established. HIV-related immunosuppression should be regarded as a risk factor for Y. pseudotuberculosis septicemia.


Asunto(s)
Bacteriemia/microbiología , Infecciones por VIH/complicaciones , Infecciones por Yersinia pseudotuberculosis/microbiología , Adulto , Femenino , Humanos , Italia , Masculino , Persona de Mediana Edad , Infecciones por Yersinia pseudotuberculosis/diagnóstico
11.
AIDS Res Hum Retroviruses ; 20(7): 709-10, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15307915

RESUMEN

The first case of septicemia due to Yersinia pseudotuberculosis in an HIV-infected person was reported. The 42-year-old woman was severely immunosuppressed despite a prolonged exposure to HAART. Specific amplicons for inv, yadA, and lcrF genes showed the pathogenetic potential of the Y. pseudotuberculosis serotype O1 isolate. A favorable clinical response to ceftriaxone and levofloxacin was observed.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/microbiología , Terapia Antirretroviral Altamente Activa/efectos adversos , Sepsis/complicaciones , Infecciones por Yersinia pseudotuberculosis/complicaciones , Yersinia pseudotuberculosis/aislamiento & purificación , Adulto , Ceftriaxona/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Femenino , Humanos , Levofloxacino , Ofloxacino/uso terapéutico , Insuficiencia del Tratamiento , Yersinia pseudotuberculosis/genética , Infecciones por Yersinia pseudotuberculosis/tratamiento farmacológico
12.
Recenti Prog Med ; 95(12): 591-603, 2004 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-15666493

RESUMEN

After careful review of evidence-based literature, clinical and laboratory criteria for diagnosis of bacterial and fungal endocarditis are examined. The choice criteria for therapy of bacterial endocarditis, both empiric and directed against a specific pathogen, are reviewed, on the basis of the clinical and epidemiological context (prosthetic or native valve, left or right heart, drug addiction). Different treatment options are proposed, based on results of antibiotic resistance testing. Indications and contraindications for a parenteral home treatment and those for surgical treatment are examined, also according to the results of ultrasonography.


Asunto(s)
Antibacterianos/uso terapéutico , Endocarditis Bacteriana/diagnóstico , Endocarditis Bacteriana/terapia , Administración Oral , Atención Ambulatoria , Antibacterianos/administración & dosificación , Procedimientos Quirúrgicos Cardíacos/normas , Contraindicaciones , Diagnóstico Diferencial , Esquema de Medicación , Farmacorresistencia Bacteriana , Ecocardiografía , Endocarditis Bacteriana/tratamiento farmacológico , Endocarditis Bacteriana/microbiología , Endocarditis Bacteriana/cirugía , Medicina Basada en la Evidencia , Prótesis Valvulares Cardíacas/microbiología , Terapia de Infusión a Domicilio/normas , Humanos , Infusiones Intravenosas
14.
J Nucl Med ; 43(1): 79-86, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11801708

RESUMEN

UNLABELLED: This study evaluated the effects of low-dose cisplatin plus 89Sr versus 89Sr alone in the treatment of painful bone metastases from prostate cancer, addressing both pain palliation and cytostatic effects. METHODS: Seventy patients with metastatic hormone-refractory prostate cancer were randomized into 2 groups: One group (arm A) received 148 MBq 89Sr plus 50 mg/m(2) cisplatin, and the other group (arm B) received 148 MBq 89Sr plus placebo. After treatment, the patients were followed up until death to evaluate the outcome variables: grade and duration of pain palliation, onset of new painful sites, changes in bone disease, global survival, serum prostate-specific antigen and alkaline phosphatase changes, and hematologic toxicity. RESULTS: Overall pain relief occurred in 91% of patients in arm A and 63% of patients in arm B (P < 0.01), with a median duration of 120 d in arm A and 60 d in arm B (P = 0.002). New painful sites on previously asymptomatic bone metastases appeared in 14% of patients in arm A and in 30% of patients in arm B (P = 0.18). The median survival without new painful sites was 4 mo in arm A and 2 mo in arm B (P = 0.04). Bone disease progression was observed in 27% of patients in arm A and in 64% of patients in arm B (P = 0.01). Median global survival after therapy was 9 mo in arm A and 6 mo in arm B (P = 0.30). Transient and moderate hematologic toxicity, as determined by World Health Organization criteria, was apparent in both arms without significant differences. CONCLUSION: The addition of a low dose of cisplatin enhances the effect of a standard dose of 89Sr without significant side effects, producing a significant improvement in pain palliation and a cytostatic effect on bone disease.


Asunto(s)
Antineoplásicos/administración & dosificación , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/radioterapia , Neoplasias Óseas/secundario , Cisplatino/administración & dosificación , Cuidados Paliativos/métodos , Neoplasias de la Próstata/patología , Radioisótopos de Estroncio/uso terapéutico , Anciano , Antineoplásicos/uso terapéutico , Neoplasias Óseas/mortalidad , Cisplatino/uso terapéutico , Terapia Combinada , Humanos , Masculino , Estudios Prospectivos , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA